PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34079014-7	2021	Ispinesib, a KIF11-inhibitor, effectively inhibited tumor proliferation in all seven cell lines.	ispinesib	0-9	kinesin family member 11	Mus musculus	13-18
34944800-8	2021	Interestingly, ispinesib and cabozantinib prevent activation of AXL, a key driver and mechanism of drug resistance in FLT3-ITD+ AML patients.	ispinesib	15-24	AXL receptor tyrosine kinase	Homo sapiens	64-67
34944800-8	2021	Interestingly, ispinesib and cabozantinib prevent activation of AXL, a key driver and mechanism of drug resistance in FLT3-ITD+ AML patients.	ispinesib	15-24	fms related receptor tyrosine kinase 3	Homo sapiens	118-122
32911668-8	2020	Therapeutic targeting of Kif11 to block the Id1-Kif11 axis was carried out using small molecular inhibitor ispinesib.	ispinesib	107-116	kinesin family member 11	Homo sapiens	25-30
33652084-0	2021	KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo.	ispinesib	31-40	kinesin family member 11	Mus musculus	0-5
33652084-9	2021	We identified substantial in vitro and in vivo anti-tumor effects of the KIF11 inhibitors filanesib and ispinesib, with filanesib demonstrating better tolerability, suggesting future use of filanesib for the treatment of aggressive meningioma.	ispinesib	104-113	kinesin family member 11	Mus musculus	73-78
35588495-0	2022	Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degraders of Nicotinamide Phosphoribosyltransferase (NAMPT).	ispinesib	0-9	nicotinamide phosphoribosyltransferase	Homo sapiens	159-164
35588495-4	2022	As a conceptual validation study, the first generation of autophagic degraders of nicotinamide phosphoribosyltransferase (NAMPT) were developed by connecting the NAMPT inhibitor and LC3-binding ispinesib through a flexible linker.	ispinesib	194-203	nicotinamide phosphoribosyltransferase	Homo sapiens	82-120
35588495-4	2022	As a conceptual validation study, the first generation of autophagic degraders of nicotinamide phosphoribosyltransferase (NAMPT) were developed by connecting the NAMPT inhibitor and LC3-binding ispinesib through a flexible linker.	ispinesib	194-203	nicotinamide phosphoribosyltransferase	Homo sapiens	122-127
32911668-8	2020	Therapeutic targeting of Kif11 to block the Id1-Kif11 axis was carried out using small molecular inhibitor ispinesib.	ispinesib	107-116	inhibitor of DNA binding 1, HLH protein	Homo sapiens	44-47
32911668-9	2020	We finally leveraged our findings to target the Id/Kif11 pathway using the small molecule inhibitor ispinesib in the Id+ CSC results combined with chemotherapy for better response in TNBC subtypes.	ispinesib	100-109	kinesin family member 11	Homo sapiens	51-56
32300151-4	2020	One such target is the mitotic kinesin KIF11, which can be inhibited with ispinesib, a potent molecularly-targeted drug.	ispinesib	74-83	kinesin family member 11	Mus musculus	39-44
32300151-6	2020	Our results demonstrate that the delivery of ispinesib is restricted by P-gp and Bcrp efflux at BBB.	ispinesib	45-54	phosphoglycolate phosphatase	Mus musculus	72-76
32300151-6	2020	Our results demonstrate that the delivery of ispinesib is restricted by P-gp and Bcrp efflux at BBB.	ispinesib	45-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-85
32300151-8	2020	We further find that elacridar-a P-gp and Bcrp inhibitor-improves brain accumulation of ispinesib, resulting in remarkably reduced tumor growth and extended survival in a rodent model of glioblastoma.	ispinesib	88-97	phosphoglycolate phosphatase	Mus musculus	33-37
32300151-8	2020	We further find that elacridar-a P-gp and Bcrp inhibitor-improves brain accumulation of ispinesib, resulting in remarkably reduced tumor growth and extended survival in a rodent model of glioblastoma.	ispinesib	88-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-46
31488701-6	2019	Surprisingly, when the cells were challenged with ispinesib, another Eg5 inhibitor, the Eg5(D130A) cells were resistant, but those expressing Eg5(L214A) were strikingly sensitive.	ispinesib	50-59	kinesin family member 11	Homo sapiens	69-72
31488701-6	2019	Surprisingly, when the cells were challenged with ispinesib, another Eg5 inhibitor, the Eg5(D130A) cells were resistant, but those expressing Eg5(L214A) were strikingly sensitive.	ispinesib	50-59	kinesin family member 11	Homo sapiens	88-91
31488701-6	2019	Surprisingly, when the cells were challenged with ispinesib, another Eg5 inhibitor, the Eg5(D130A) cells were resistant, but those expressing Eg5(L214A) were strikingly sensitive.	ispinesib	50-59	kinesin family member 11	Homo sapiens	88-91
22248262-6	2012	Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition.	ispinesib	121-130	ETS transcription factor ERG	Homo sapiens	141-145
30410329-7	2018	Results: Results are obtained to depict the dynamics induced by ispinesib, when used as an inhibitor of kinesin Eg5, on cancer cell lines.	ispinesib	64-73	kinesin family member 11	Homo sapiens	112-115
23658017-0	2013	"Snapshots" of ispinesib-induced conformational changes in the mitotic kinesin Eg5.	ispinesib	15-24	kinesin family member 11	Homo sapiens	79-82
23658017-4	2013	This loop is longest in the mitotic kinesin Eg5 and is the target for a number of small molecule inhibitors, including ispinesib, which is being used in clinical trials in patients with cancer.	ispinesib	119-128	kinesin family member 11	Homo sapiens	44-47
23658017-5	2013	In this study, we have used x-ray crystallography to identify a new structure of an Eg5-ispinesib complex and have combined this with transient state kinetics to identify a plausible sequence of conformational changes that occur in response to ispinesib binding.	ispinesib	88-97	kinesin family member 11	Homo sapiens	84-87
23658017-6	2013	Our results demonstrate that ispinesib-induced structural changes in L5 from Eg5 lead to subsequent changes in the conformation of the switch II loop and helix and in the neck linker.	ispinesib	29-38	kinesin family member 11	Homo sapiens	77-80
23875972-2	2013	The aim of this study was to investigate the underlying molecular mechanism of resistance developed by the mitotic kinesin Eg5 against the potent second-generation ispinesib analogue SB743921 (1), a phase I/II clinical candidate.	ispinesib	164-173	kinesin family member 11	Homo sapiens	123-126
23444224-6	2013	Phenotypes that were observed following siRNA-mediated knockdown of KIF11 (kinesin family member 11) were reproduced by inhibition of KIF11 using the small-molecule inhibitor ispinesib (SB-715992).	ispinesib	175-184	kinesin family member 11	Mus musculus	68-73
23444224-6	2013	Phenotypes that were observed following siRNA-mediated knockdown of KIF11 (kinesin family member 11) were reproduced by inhibition of KIF11 using the small-molecule inhibitor ispinesib (SB-715992).	ispinesib	175-184	kinesin family member 11	Mus musculus	75-99
23444224-6	2013	Phenotypes that were observed following siRNA-mediated knockdown of KIF11 (kinesin family member 11) were reproduced by inhibition of KIF11 using the small-molecule inhibitor ispinesib (SB-715992).	ispinesib	175-184	kinesin family member 11	Mus musculus	134-139
23444224-6	2013	Phenotypes that were observed following siRNA-mediated knockdown of KIF11 (kinesin family member 11) were reproduced by inhibition of KIF11 using the small-molecule inhibitor ispinesib (SB-715992).	ispinesib	186-195	kinesin family member 11	Mus musculus	68-73
23444224-6	2013	Phenotypes that were observed following siRNA-mediated knockdown of KIF11 (kinesin family member 11) were reproduced by inhibition of KIF11 using the small-molecule inhibitor ispinesib (SB-715992).	ispinesib	186-195	kinesin family member 11	Mus musculus	75-99
23444224-6	2013	Phenotypes that were observed following siRNA-mediated knockdown of KIF11 (kinesin family member 11) were reproduced by inhibition of KIF11 using the small-molecule inhibitor ispinesib (SB-715992).	ispinesib	186-195	kinesin family member 11	Mus musculus	134-139
22993085-5	2012	In this study, the crystal structure of the Eg5 motor domain in complex with ispinesib, supported by kinetic and thermodynamic binding data, is reported.	ispinesib	77-86	kinesin family member 11	Homo sapiens	44-47
22993085-6	2012	Ispinesib occupies the same induced-fit pocket in Eg5 as other allosteric inhibitors, making extensive hydrophobic interactions with the protein.	ispinesib	0-9	kinesin family member 11	Homo sapiens	50-53
22248262-6	2012	Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition.	ispinesib	121-130	peptidylprolyl isomerase G	Homo sapiens	150-153
19545421-6	2009	Due to the brain location of the tumor, the potential target inhibition for anticancer therapy must exhibit a manageable neurotoxicity profile in the concentration range in which the compounds show anti-proliferative activity.Kinesin KIF11 inhibition by small molecules such as Monastrol or Ispinesib is currently under investigation in the field of malignant tumors.	ispinesib	291-300	kinesin family member 11	Homo sapiens	234-239
19545421-8	2009	RESULTS: In this study the target was validated using a set of well characterised and potentially specific small molecule inhibitors of KIF11: an ispinesib analog, Monastrol, a Merck compound and 3 simplified derivatives of the Merck compound.	ispinesib	146-155	kinesin family member 11	Homo sapiens	136-141
19545421-12	2009	Furthermore, ispinesib analog increased caspase 3/7-induced apoptosis in U87MG cells.	ispinesib	13-22	caspase 3	Homo sapiens	40-49